Product Description
Mechanisms of Action: SDC Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Biotest
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Multiple Myeloma|Transitional Cell Carcinoma|Triple Negative Breast Cancer|Bladder Cancer
Phase 1: Multiple Myeloma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT01638936 | P2 |
Completed |
Multiple Myeloma |
2018-10-30 |
53% |
INTRAIN-BB (INdaTuximab RAvtansin effect IN Breast and Bladder cancer) | P2 |
Completed |
Transitional Cell Carcinoma|Bladder Cancer|Triple Negative Breast Cancer |
2017-08-04 |
|
NCT01001442 | P2 |
Completed |
Multiple Myeloma |
2014-07-01 |
|
NCT00723359 | P1 |
Completed |
Multiple Myeloma |
2012-04-01 |